ATB Cormark Capital Markets Downgrades Aurora Cannabis (TSE:ACB) to Tender

Aurora Cannabis (TSE:ACB – Get Free Report) was downgraded by equities research analysts at ATB Cormark Capital Markets from an “outperform” rating to a “tender” rating in a research note issued to investors on Wednesday,BayStreet.CA reports. They presently have a C$5.60 target price on the stock, down from their previous target price of C$6.50. ATB Cormark Capital Markets’ price target indicates a potential upside of 5.07% from the company’s current price.

ACB has been the topic of a number of other reports. TD dropped their price target on Aurora Cannabis from C$10.00 to C$8.00 and set a “buy” rating on the stock in a report on Friday, June 12th. BMO Capital Markets upgraded Aurora Cannabis to a “hold” rating in a research note on Wednesday, August 5th. Finally, Canaccord Genuity Group decreased their target price on Aurora Cannabis from C$6.50 to C$5.00 and set a “buy” rating for the company in a research report on Tuesday, June 30th. Two research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, Aurora Cannabis presently has a consensus rating of “Moderate Buy” and an average price target of C$6.20.

Get Aurora Cannabis alerts:

Get Our Latest Report on ACB

Aurora Cannabis Stock Up 4.5%

TSE:ACB traded up C$0.23 on Wednesday, hitting C$5.33. The stock had a trading volume of 459,104 shares, compared to its average volume of 425,306. The company has a debt-to-equity ratio of 4.30, a quick ratio of 2.48 and a current ratio of 5.36. The stock has a market cap of C$330.23 million, a P/E ratio of -2.75 and a beta of 0.25. Aurora Cannabis has a 1 year low of C$3.59 and a 1 year high of C$9.33. The firm’s fifty day simple moving average is C$4.10 and its two-hundred day simple moving average is C$4.58.

Aurora Cannabis (TSE:ACB – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported C($0.07) EPS for the quarter. The firm had revenue of C$67.55 million for the quarter. Aurora Cannabis had a negative return on equity of 5.21% and a negative net margin of 9.53%. Analysts predict that Aurora Cannabis will post -0.22 earnings per share for the current year.

Aurora Cannabis Company Profile

(Get Free Report)

Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael ’71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.

Read More

• Five stocks we like better than Aurora Cannabis
• Target Is Winning Shoppers Back—Can the Rally Reach $180?
• IonQ’s Space Contract Points to a New Frontier for Quantum Investors
• Is Apple’s AI Strategy Smarter Than Skeptics Think?
• Why Lowe’s Could Be a Bargain Before Housing Recovers

Receive News & Ratings for Aurora Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurora Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.